A virologist was awarded a $2 million NIH grant to study how virus-infected cells live and die, focusing on cell-death pathways that can determine disease progression and antiviral response. The funding highlights continued agency emphasis on foundational virology mechanisms that can later inform therapeutic target selection. By supporting mechanistic work on infected-cell survival and death, the program targets gaps that can affect multiple virus families and therapeutic approaches, from antiviral development to immune modulation. For biotech researchers, the award points to near-term NIH support for upstream biology that may translate into platform-relevant drug discovery later.